Published in final edited form as:

Am J Alzheimers Dis Other Dement. 2010 May ; 25(3): 233–238. doi:10.1177/1533317509357736.

Effects of Apolipoprotein E- ϵ 4 and - ϵ 2 in Amnesic Mild Cognitive Impairment and Dementia in Shanghai: SCOBHI-P

Amy R. Borenstein, PhD, MPH¹, James A. Mortimer, PhD¹, Ding Ding, MD, MPH², Gerard D. Schellenberg, PhD³, Charles DeCarli, MD⁴, Qianhua Zhao, MD, PhD², Cathleen Copenhaver, MSPH¹, Qihao Guo, MD², Shugang Chu, MD, PhD², Douglas Galasko, MD⁵, David P. Salmon, PhD⁵, Qi Dai, MD, PhD⁶, Yougui Wu, PhD¹, Ronald Petersen, MD, PhD⁷, and Zhen Hong, MD²

¹ Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA

² University of Fudan School of Public Health, Huashan Hospital, Shanghai, China

³ University of Pennsylvania, Philadelphia, PA, USA

⁴ University of California-Davis, Sacramento, CA, USA

⁵ University of California-San Diego, San Diego, CA, USA

⁶ Vanderbilt University, Nashville, TN, USA

⁷ Mayo Clinic, Rochester, MN, USA

Abstract

Objective—To determine apolipoprotein E (APOE)- ϵ 4 and - ϵ 2 frequencies and risk of mild cognitive impairment (MCI) and dementia in Shanghai, China.

Methods—A total of 34 MCI and 34 dementia cases were recruited from an urban Memory Disorders Clinic and 32 controls were recruited from a residential community served by the clinic. Apolipoprotein E was genotyped using standard methods.

Results—Among controls, frequencies were ϵ 2, 0.11; ϵ 3, 0.84; and ϵ 4, 0.05; among MCI, 0.05, 0.77, and 0.18; and for dementia, 0.02, 0.84, and 0.15, respectively. In education-adjusted models, the odds ratio (OR) = 5.6 for dementia (95% CI = 1.09–29.3) and 4.7 for MCI (95% CI = 0.90–25.2) associated with any ϵ 4 allele. The ϵ 2 allele was inversely associated with dementia (OR = 0.12, 95% CI = 0.013–0.997) and MCI (OR = 0.38, 95% CI = 0.08–1.61).

Conclusions—APOE- ϵ 4 increases and - ϵ 2 decreases the risk of dementia vs normal cognition. Similar trends were observed for amnesic mild cognitive impairment (aMCI).

Keywords

apolipoprotein E; dementia; mild cognitive impairment; China

Corresponding Author: Amy R. Borenstein, Department of Epidemiology and Biostatistics, University of South Florida, 13201 Bruce B. Downs Blvd, Tampa, FL 33612, USA, aborenst@health.usf.edu.

Declaration of Conflicting Interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Introduction

The apolipoprotein E (APOE)- ϵ 4 allele is a strong risk factor for Alzheimer's disease (AD) among different ethnic groups^{1–5} and age at onset is influenced by the number of APOE alleles.⁶ Among African Americans, there is heterogeneity in risk of memory impairment from APOE, some showing similar effects as in Caucasians,⁷ while others show no association.^{2,8} The association between APOE- ϵ 2 and AD is less clear, with some studies finding a clear inverse association^{2,9,10} and others finding no association.¹¹

The effect of APOE isoforms on the risk of dementia and mild cognitive impairment (MCI) in Chinese populations is of interest because the frequency of the risk allele for AD, APOE- ϵ 4, is thought to be lower in China.¹² Therefore, the lower reported prevalence of dementia in China in some studies^{3,13,14} may be in part explained by lower ϵ 4 frequencies. The question of how the isoforms (ϵ 2 and ϵ 4) relate to dementia risk in non-Caucasians is important because it may point to a common pathogenesis across racial/ethnic groups.

Few studies have examined the associations between both APOE isoforms and MCI. It remains unclear at what stage ϵ 4 and ϵ 2 affect conversion: from normal cognition to MCI or from MCI to dementia/AD. If these effects are largely complete by the time a person meets criteria for MCI, then ϵ 4 and ϵ 2 would be acting early in the disease process to modify risk. It has been suggested that persons who are ϵ 4 positive and develop AD show hypometabolism in temporal parietal regions while they are still asymptomatic.¹⁵ Carriers of the ϵ 4 allele can be distinguished by abnormal positron emission tomography (PET) scans in comparison with noncarriers when they are in their twenties.¹⁶ If ϵ 4 and perhaps ϵ 2 have early effects, APOE may represent a viable target for preventing dementia. It is noteworthy that patients with MCI who are APOE- ϵ 4 positive and who show increased amyloid burden on Pittsburgh compound-B positron emission tomography (PiB-PET) imaging have an increased rate of progression to AD.¹⁷ This suggests that even if the role of APOE- ϵ 4 begins early in life, it may nevertheless affect the rate of progression of the clinical expression of disease late in life.

In this study, we examined APOE allele frequencies in a sample of cognitively normal, community-dwelling elderly individuals and in cases with MCI and dementia in Shanghai, China.

Methods

Study Population

Subjects were participants in the Shanghai Community Brain Health Initiative-Pilot (SCOBHIP), a case-control study of individuals living in Shanghai, China. The target sample included approximately equal numbers of participants with normal cognition (controls), MCI, and mild-to-moderate dementia living in the community. Cases of dementia and MCI were identified from the Memory Disorders Clinic (MDC) at Huashan Hospital, located in the Jing'an District of Shanghai. We identified these cases from incident cases that had first been seen at the MDC between May 2007 and November 2008. One hundred and nine cases and their informants were invited to participate; of these, 58 were recruited (53.2%). Of the 51 not recruited, 42 refused, 8 were unreachable, and 1 had a stroke. Potential controls were identified using a government-maintained "name list," which includes the name, sex, age, address, and telephone number of all residents. This list is kept current by the neighborhood administration office, which keeps track of all individuals living in that neighborhood, including in- and out-migration, as well as deaths. For this study, we obtained the name list for Jing'an and focused on a resident group in a defined geographic area, consisting of 5 buildings in the Jingansi Temple Community. Potential participants were approached at the door to describe the study. Of 71 potential participants from the name list, 10 refused (14%). An additional 3 names on

the name list were unreachable. The recruitment rate in the community was 81.6%. When the 58 residents in the community were clinically evaluated, 2 met study criteria for dementia (3.5%) and 12 met Petersen criteria for MCI (20.6%). These 14 individuals were added to the case pool. Of the 116 cases and controls, we frequency matched a set of 32 normal controls, 34 MCI, and 34 dementia cases by age and sex for our analyses.

Of 34 participants who were diagnosed with MCI, 4 (12%) were found to have the nonamnestic type (naMCI), and 30 (88%) had the amnestic type (aMCI). We excluded naMCI cases from our analyses, because there was an insufficient number to analyze separately and we were interested in how dementia risk factors differed from aMCI, because aMCI progresses to dementia more commonly than naMCI.¹⁸

We obtained written informed consent from all cases and controls and their proxies. The study was approved by the Huashan Hospital, Fudan University in Shanghai, China, and the University of South Florida Institutional Review Boards.

Dementia and MCI Diagnoses

All individuals participated in a detailed physical and neurologic evaluation by study neurologists (QZ and QG), neuropsychological testing by trained, certified psychometrists, magnetic resonance imaging (MRI), blood donation, medical and family history, and other epidemiologic evaluations. The neuropsychological test battery consisted of the following instruments normed in Shanghai (by QG): modern Chinese Cognitive Abilities Screening Instrument (CASI),¹⁹ WAIS-R Digit Span,²⁰ Bell Cancellation Test,²¹ WMS Logical Memory Test²² (immediate and delayed recall), Rey-Osterrieth Complex Figure²³ (copying and recall), Stroop Test,²⁴ Auditory Verbal Learning Test,²⁵ Category Verbal Fluency Test, WAIS-R Similarities Test,²⁰ Trail-Making Test,²⁶ Clock-Drawing Test,²⁷ Boston Naming Test,²⁸ and Mattis Dementia Rating Scale.²⁹ Consensus diagnostic conferences were conducted by the Chinese team (DD, QZ, QG, and ZH) with a subset of difficult cases also attended by members of the US team (RP, DG, DPS, ARB, and JAM). Dementia and its subtypes were diagnosed by criteria from the *Diagnostic and Statistical Manual* (Fourth Edition),³⁰ the National Institute of Neurological and Communicative Disorders and Related Disorders Association (NINCDS-ADRDA)³¹ criteria for AD, and the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia.³² Mild cognitive impairment and amnestic versus non-amnestic subtypes were applied from Petersen criteria^{33,34} except that there was no requirement of a memory complaint from the participant corroborated by the informant. Objective memory impairment for age was based on norms developed by the neuropsychologist (QG) in Shanghai; we used the Chinese AVLT-long delay as evidence of memory impairment.^{35,36} Preserved cognitive function in other domains was based on the neuropsychological battery. Largely intact activities of daily living was assessed by a 23-item instrument developed in Shanghai. All participants were administered detailed physical and neurologic examinations by study neurologists, and diagnoses were made for all participants and dementia criteria were ruled out for cases with MCI. Subtypes of MCI (amnestic MCI, single domain; amnestic MCI, multiple domain; non-amnestic MCI, single domain; non-amnestic subtype, multiple domain) were distinguished based on whether memory was impaired, in addition to language, attention, executive function, and visuospatial abilities on neuropsychological testing.

Qualitative assessment of whole brain atrophy and macrovascular lesions from each participant's MRI were used to assist in the diagnosis and subtyping of dementia.

Apolipoprotein E Genotyping

We obtained venous blood samples collected into EDTA anticoagulant from all cases and controls at Hua Shan Hospital. Lab technicians were blind to the diagnosis of the participants. Methods followed those of Emi³⁷ and Hixson.³⁸

Other Covariates

An extensive risk factor questionnaire was administered to all proxies and all controls. Age was reported by proxies of cases and controls as was the highest level of education completed by the case and control. Educational level was coded as 0: no school; 1: primary school; 2: middle school; 3: high school; 4: college or university and 5: above university (postgraduate school). We collected the continuous number of years of education achieved, but 4 participants had missing data; therefore, educational level from the proxy interview was used instead.

Statistical Analyses

We used analysis of variance (ANOVA) to describe the differences between normal controls, aMCI, and patients with dementia for continuous variables, with Tukey multiple comparison procedure used for comparisons of individual means. For categorical variables, χ^2 was used to test for overall significance. Logistic regression models were built to predict the comparisons between dementia and controls and aMCI and controls for APOE genotypes. Dichotomous variables were created for “any $\epsilon 4$ ” and “any $\epsilon 2$ ” including $\epsilon 2\epsilon 4$ genotypes (included as “any $\epsilon 4$ ” in the $\epsilon 4$ analysis and “any $\epsilon 2$ ” in the $\epsilon 2$ analysis). Because the groups were well matched on age and sex, each model was run with APOE alone and then with education added to the model. All analyses were conducted using statistical analysis system (SAS) version 9,³⁹ with P values less than .05 (2-tailed) interpreted as being statistically significant.

Results

We compared the age and sex of the 64 participating cases with the 51 nonresponding cases. The mean age among the responding cases and their informants was 74.6 (SD = 5.0) and among nonresponding cases and their informants 75.6 (SD = 4.9; $t = 1.08$, $P > .20$). For sex, $\chi^2 = 0.47$, $P = .49$. Nonparticipants from the community were older (mean 76.1 [SD = 5.96] vs mean 73.4 [SD = 5.6]), but not significantly so ($P > .10$). Community-based nonparticipants also were more likely to be male (69.2% vs 51.6%), but this difference also was not statistically significant ($P = .28$).

Characteristics of the sample and the 3 groups are shown in Table 1. Mean age did not differ among groups ($F = .63$, $P = .54$). Matching on sex was achieved, with men and women comprising about half of each group ($P = .96$). Although educational attainment did not differ significantly between groups, 40% of aMCI had a college education or more compared with about 25% of the other 2 groups. The 3 diagnostic groups differed in mean Mattis Dementia Rating Scale score ($F = 54.4$; $P < .0001$). After adjustment for multiple comparisons (Tukey), all means were significantly different from one another.

Table 2 shows the genotypes for the 3 groups. There were no $\epsilon 2\epsilon 2$ genotypes nor were any of the controls $\epsilon 4\epsilon 4$. Allele frequencies also are shown in Table 2.

Tables 3 and 4 show logistic regressions conducted to assess the risk of dementia and MCI from “any $\epsilon 4$ ” and “any $\epsilon 2$ ” allele, respectively. The adjusted odds ratio (OR) for dementia associated with $\epsilon 4$ was 5.6 (95% CI = 1.09–29.3), and for MCI, 4.7 (95% CI = 0.9–25.2). Corresponding models for $\epsilon 2$ were associated with inverse risk: for dementia, OR = 0.12 (95% CI = 0.01–0.997) and for MCI, OR = 0.37 (95% CI = 0.08–1.61). The ORs for MCI associated

with both $\epsilon 4$ and $\epsilon 2$ were in the expected directions, although the power to detect a significant association was likely too low.

Discussion

The $\epsilon 4$ allele frequency among normal controls in our sample was 5%, considerably lower than in most Caucasian populations, where the frequency is 14%.^{2,40} Despite the low frequency of $\epsilon 4$, this variant was strongly associated with dementia. The OR for dementia (5.6) was in the same range as most studies of Caucasians.² A very similar OR was found for the association between $\epsilon 4$ and MCI. However, due to limited power, it was not statistically significant. For $\epsilon 2$, we found the reverse trend: a statistically inverse association between $\epsilon 2$ and dementia and a trend for an inverse association with MCI. Again, the strengths of the $\epsilon 2$ association are in the same range as published studies.²

We found that frequencies of $\epsilon 2$ and $\epsilon 4$ were very similar in aMCI and dementia, and both differed substantially from the frequencies of these alleles in controls. Therefore, APOE appears to be having its effect relatively early in the disease process. If APOE genotype influenced AD pathology later, one would have seen a difference between dementia cases and aMCI. If the influence was gradual, one would expect all 3 groups to differ by APOE- $\epsilon 4$ frequency. The finding of similar frequencies between aMCI and dementia suggests that most of the effect may be evident by the time individuals are diagnosable as aMCI. To evaluate this hypothesis further, a large, longitudinal study examining the evolution of aMCI to dementia and its subtypes would be necessary, in which one could also determine whether there is heterogeneity in the association between APOE and dementia versus APOE and AD.

Our estimate of the $\epsilon 2$ allele frequency is relatively high, even among Chinese studies, but agrees with those from Beijing¹² and Hifei.⁴¹ More recent studies conducted among Caucasians show significant heterogeneity of $\epsilon 2$ frequencies, ranging from 1% to 15%.^{42,43} The low frequency of $\epsilon 2$ from Finland has been noted^{2,44} and may represent an outlier among Caucasian frequencies. Some studies of Caucasians^{43,45,46} show $\epsilon 2$ frequencies close to our estimate of 11%.

The $\epsilon 4$ variant of APOE is a strong predictor of AD and is strongly related to its pathology.^{5,47,48} Studies from China^{3,4,49} and Taiwan^{11,14,50} have replicated this finding and have also shown that in AD $\epsilon 4$ participants progress faster than non- $\epsilon 4$ participants.⁵¹ A large study from Taiwan found higher mean cholesterol levels in $\epsilon 4$ s and lower levels in $\epsilon 2$ s, compared with $\epsilon 3$ homozygotes.⁵² Some studies have found a clear protective effect of the $\epsilon 2$ allele.^{2,9} In Sweden, this effect was limited to individuals younger than 85.⁵³ However, in Taiwan, $\epsilon 2$ was not associated with a reduced risk of AD.¹¹ In a recent study⁵⁴ of people dying in their 90s, $\epsilon 2$ carriers were not more likely to express dementia clinically but were 7.8 times more likely to meet neuropathologic criteria for AD compared with the $\epsilon 3\epsilon 3$ genotype (95% CI = 1.5–40.2). The protective effect of $\epsilon 2$ on dementia that we found is consistent with the relatively young mean age of our sample.

The mechanisms by which APOE genotypes lead to MCI and dementia remain controversial. It is known that APOE performs important functions in transporting cholesterol and phospholipids from astrocytes to neurons and that the absence of APOE results in dysfunction of terminal remodeling and synaptic replacement.⁵⁵ Individuals homozygous for $\epsilon 2$ express the highest level of APOE and those homozygous for $\epsilon 4$ the lowest. Apo-lipoprotein E- $\epsilon 2$ and - $\epsilon 3$ may have neuroprotective and neurotrophic roles in the normal aging brain and, therefore, it has been argued that individuals who do not possess an $\epsilon 2$ (or $\epsilon 3$) allele may be at risk of AD-type pathology.⁴⁷ Many studies have found that risk of AD increases with $\epsilon 2 < \epsilon 3 < \epsilon 4$,^{10,56–58} and that a gene dosage effect is evident with $0 \epsilon 4 < 1 \epsilon 4 < 2 \epsilon 4$.^{2,6}

Participants who carry the $\epsilon 2\epsilon 4$ genotype are sometimes excluded from analyses.⁵⁹ In a meta-analysis, individuals carrying this genotype were still at higher risk.² We categorized these individuals as possessing an $\epsilon 4$ allele and included them in the category of ≥ 1 $\epsilon 4$; we also included them in our $\epsilon 2$ analyses when considering ≥ 1 $\epsilon 2$. Exclusion of participants with the $\epsilon 2\epsilon 4$ in other analyses (not shown) had little effect on the ORs.

Only 2 studies have examined the role of $\epsilon 4$ on MCI in China and Taiwan.^{41,60} In Hefei, China, a memory clinic-based and nursing home sample of 28 patients with MCI and 30 controls was recruited. Apolipoprotein E- $\epsilon 4$ was found to predict MCI status compared with controls. In Taiwan, an ongoing cohort study at Taipei Veterans General Hospital's neurology clinics was conducted from 1990 to 2003.⁶⁰ Fifty-eight participants with MCI were compared with 20 controls. The $\epsilon 4$ allele was present in a large proportion of the controls (20%) and, while 25.9% of the MCI participants possessed the $\epsilon 4$ allele, the difference was only marginally significant ($P = .06$). In our study, one or more $\epsilon 4$ alleles was present among 9.4% of our controls. Methodologic techniques used to select samples for study may explain these differences.

Strengths of our study include the detailed clinical work-ups done on all participants, including controls. In addition, controls in our study were recruited from the community served by the Memory Disorders clinic from which the cases were identified. In Shanghai, there is no medical referral system. Individuals living in the community can seek care at any hospital in the city. Hua Shan Hospital, located in the community in which controls were recruited, is known in Shanghai for its Memory Disorders clinic. Therefore, individuals wishing to be seen by well-known neurologists come to the clinic and wait until they are seen the same morning. Therefore, there is less referral bias in this population than would be seen in a similar study conducted in the United States. This minimizes the referral bias in our study but may not eliminate it.

Limitations of our study include the relatively small size and cross-sectional nature of the study. This study was designed as a feasibility pilot study for a larger follow-on study. The percentage of dementia (3.5%) and cases with MCI (20.6%) found in the community of potential controls is likely illustrative of the frequency of MCI and dementia that is undiagnosed in the urban community in Shanghai.

Further research on the roles of the APOE- $\epsilon 2$ and - $\epsilon 4$ alleles require larger, prospective studies in China, in which specific genotypes can be examined in relation to incident dementia and MCI risk. However, our study demonstrates that the pathogenesis of dementia and aMCI is similar in Chinese and Caucasians with regard to the role that APOE plays.

Acknowledgments

Funding

NIH R21 AG028182

References

1. Mak YT, Chiu H, Woo J, et al. Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. *Neurology* 1996;46(1):146–149. [PubMed: 8559364]
2. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. *JAMA* 1997;278(16):1349–1356. [PubMed: 9343467]
3. Katzman R, Zhang MY, Chen PJ, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. *Neurology* 1997;49(3):779–785. [PubMed: 9305340]

4. Zhang JG, Yang JG, Lin X, et al. Apolipoprotein E ϵ 4 allele is a risk factor for late-onset Alzheimer's disease and vascular dementia in Han Chinese. *Int J Geriatr Psychiatry* 2001;16(4):436–441. [PubMed: 11333434]
5. Bennett DA, Wilson RS, Schneider JS, et al. Apolipoprotein E ϵ 4 allele, AD pathology, and the clinical expression of Alzheimer's disease. *Neurology* 2003;60(2):246–252. [PubMed: 12552039]
6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. *Science* 1993;261(5123):921–923. [PubMed: 8346443]
7. Murrell JR, Price B, Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. *Arch Neurol* 2006;63(3):431–434. [PubMed: 16533971]
8. Borenstein A, Mortimer JA, Wu Y, et al. Apolipoprotein E and cognition in population-based samples of African Americans and Whites. *Ethnicity and Disease* 2006;16(1):9–15. [PubMed: 16599342]
9. Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon 2 allele and decline in episodic memory. *J Neurol Neurosurg Psych* 2002;73(6):672–677.
10. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Gen* 1994;7(2):180–184.
11. Lung FW, Yen YC, Chou LJ, Hong CJ, Wu CK. The allele interaction between apolipoprotein ϵ 2 and ϵ 4 in Taiwanese Alzheimer's disease patients. *Acta Psychiatr Scand* 2005;111(1):38–43. [PubMed: 15636592]
12. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 1988;8(1):1–21. [PubMed: 3277611]
13. Chen HH, Hu CJ. The genetic studies of dementias in Taiwan. *Acta Neurol Taiwan* 2006;15(1):60–63. [PubMed: 16599291]
14. Lai CL, Tai CT, Lin SR, Lin RT, Yang YH, Liu CK. Apolipoprotein E in Taiwan Chinese patients with dementia. *Dement Geriatr Cogn Disord* 2003;16(4):208–211. [PubMed: 14512715]
15. Petersen, RC. *Mild Cognitive Impairment: Aging to Alzheimer's disease*. New York, NY: Oxford University Press; 2003. p. 238
16. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc Natl Acad Sci* 2004;101(1):284–289. [PubMed: 14688411]
17. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. *Neurology* 2009;73(10):744–745. [PubMed: 19641169]
18. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. *Dement Geriatr Cogn Disord* 2006;22(4):312–319. [PubMed: 16940725]
19. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiologic studies of dementia. *Int Psychogeriatr* 1994;6(1):45–56. [PubMed: 8054493]
20. Wechsler, D. *WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised*. New York, NY: Psychological Corporation; 1981.
21. Gauthier L, Dehaut F, Joanette Y. The Bells test: a quantitative and qualitative test for visual neglect. *Int J Clin Neuropsychol* 1989;11(2):49–54.
22. Wechsler, D. *Wechsler Memory Scale-Revised Manual*. San Antonio: Psychological Corporation; 1987.
23. Rey A. L-examen psychologique dans les cas d'encephalopathie traumatique. *Arch Psychologie* 1941;28:286–340.
24. Golden, CJ. *Stroop Color and Word Test*. Chicago, IL: Stoelting Company; 1978.
25. Schmidt, M. *Rey Auditory Verbal Learning Test. A Handbook*. Los Angeles, CA: Western Psychological Services; 1996.
26. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. *Percept Motor Skills* 1958;8:271–276.

27. Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. *Brain Cogn* 1992;18(1):70–87. [PubMed: 1543577]
28. Kaplan, EF.; Goodglass, H.; Weintraub, S. The Boston Naming Test. Philadelphia, PA: Lea & Fibiger; 1983.
29. Mattis, S. Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources; 1988.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington DC: APA; 2000.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34(7):939–944. [PubMed: 6610841]
32. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* 1993;43(2):250–260. [PubMed: 8094895]
33. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;58(12):1985–1992. [PubMed: 11735772]
34. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;256(3):183–194. [PubMed: 15324362]
35. Guo Q, Lu CZ, Hong Z. Reliability and validity of auditory verbal learning test on Chinese elderly patients. *Chinese Mental Health J* 2001;15(1):13–15.
36. Guo Q, Sun YM, Yu PM, Hong Z, Lu CZ. Norms for Auditory Verbal Learning Test in the normal aged in Chinese community. *Chinese J Clin Psychol* 2007;15(2):132–135.
37. Emi M, Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. *Genomics* 1988;3(4):373–379. [PubMed: 3243553]
38. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res* 1990;31:545–548. [PubMed: 2341813]
39. SAS Institute. SAS System for Microsoft Windows (version 9). Cary, NC: SAS Institute Inc; 2003.
40. Bertram, L.; Lill, CM.; McQueen, MB.; Schieide, BMM.; Zauf, U. Alzgene: Published AD candidate genes. 2009 [Accessed August 17, 2009]. www.alzgene.org/meta.asp?geneID=83. Alzheimer Research Forum, www.alzforum.org
41. Wang QS, Tian L, Huang YL, Qin S, He LQ, Zhou JN. Olfactory identification and apolipoprotein E ϵ 4 allele in mild cognitive impairment. *Brain Res* 2002;951(1):77–81. [PubMed: 12231459]
42. Lehtovirta M, Helisalmi S, Mannermaa A, et al. Apolipoprotein E polymorphism and Alzheimer's disease in Eastern Finland. *Neurosci Lett* 1995;185(1):13–15. [PubMed: 7731544]
43. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E ϵ 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. *Hum Mol Gen* 1994;3(4):569–574. [PubMed: 8069300]
44. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann Q. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. *J Lipid Res* 1986;27(3):227–235. [PubMed: 3734624]
45. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer Disease. *Am J Hum Gen* 1994;54(4):643–649.
46. Kukull WA, Schellenberg GD, Bowen JD, et al. Apolipoprotein E in Alzheimer's Disease risk and case detection: a case-control study. *J Clin Epidemiol* 1996;49(10):1143–1148. [PubMed: 8826994]
47. Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. *Journal of Alzheimer's Disease* 2002;4(3):145–154.
48. Mortimer JA, Snowden DA, Markesbery WR. The effect of APOE- ϵ 4 on dementia is mediated by Alzheimer neuropathology. *Alzheimer Dis Assoc Disord* 2009;23(2):152–157. [PubMed: 19484916]
49. Wu YN, Zhang JW, Zhang ZX, Qu QM, Chen D. An association analysis of apolipoprotein E genotypes with Alzheimer's disease in Chinese population. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2001;23(5):450–454. [PubMed: 12905860]

50. Huang HM, Kuo YM, Ou HC, Lin CC, Chuo LJ. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. *Journal of Neur Transm* 2002;109(11):1415–1421.
51. Lam LC, Tang NL, Ma SL, et al. Apolipoprotein epsilon4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer's disease. *Am J Alzheimer's Dis Other Demen* 2006;21(2):92–99.
52. Liu HC, Hong CJ, Wang SJ, et al. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. *Neurology* 1999;53(5):962–966. [PubMed: 10496253]
53. Qiu C, Kivipelto M, Agüero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. *J Neurol Neurosurg Psych* 2004;75(6):828–833.
54. Berlau DJ, Corrada MM, Head E, Kawas CH. APOE ε2 is associated with intact cognition by increased Alzheimer pathology in the oldest old. *Neurology* 2009;72(9):829–834. [PubMed: 19255410]
55. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. *Alzheimer's Dementia* 2008;4(1):S91–S97.
56. Holtzman DM. In vivo effects of ApoE and clusterin on amyloid-β metabolism and neuropathology. *J Mol Neurosci* 2004;23(3):247–254. [PubMed: 15181253]
57. Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. *Ann Neurol* 1995;38(2):254–259. [PubMed: 7654074]
58. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. *Annu Rev Neurosci* 1996;19:53–57. [PubMed: 8833436]
59. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. *Atherosclerosis* 2001;154(3):529–537. [PubMed: 11257253]
60. Wang PN, Lirng JF, Lin KN, Chang FC, Liu HC. Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. *Neurobio Aging* 2006;27(12):1797–1806.

Table 1

Descriptive Comparisons of Diagnostic Groups

	Controls (n = 32)	aMCI (n = 30)	Dementia (n = 34)
Mean age (SD)	73.4 (5.5)	74.8 (4.0)	74.4 (5.6)
Men (n and %)	16 (50.0)	15 (50.0)	18 (52.9)
Education (n and %)			
No or primary school	6 (18.8)	5 (16.7)	14 (41.2)
Middle school	7 (21.9)	3 (10.0)	5 (14.7)
High school	11 (34.4)	10 (33.3)	6 (17.6)
College or more	8 (25.0)	12 (40.0)	9 (26.4)
Mattis Dementia Rating Scale Score	134.7 (6.4)	123.2 (10.7)	103.0 (17.4)

Abbreviation: aMCI, amnesic mild cognitive impairment.

Table 2
Frequencies of Apolipoprotein E (APOE) Genotypes and Alleles in Diagnostic Groups

	Frequencies							
	ε2ε3	ε2ε4	ε3ε3	ε3ε4	ε4ε4	ε2	ε3	ε4
Controls	6 (18.75)	1 (3.13)	23 (71.88)	2 (6.3)	0 (0)	0.11	0.84	0.05
aMCI	1 (3.33)	2 (6.67)	20 (66.67)	5 (16.67)	2 (6.67)	0.05	0.77	0.18
Dementia	1 (2.94)	0 (0)	24 (70.59)	8 (23.53)	1 (2.94)	0.02	0.84	0.15
	8	3	67	15	3			

Abbreviation: aMCI, amnesic mild cognitive impairment.

Table 3

Logistic Regressions Comparing Dementia Cases to Controls and aMCI Cases to Controls for APOE-ε4, With and Without Adjustment for Educational Level

	Dementia (OR, 95% CI)		aMCI (OR, 95% CI)	
Model 1 ^a	5.4	1.07–27.3	4.6	0.87–24.1
Model 2 ^b	5.6	1.09–29.3	4.7	0.90–25.2

Abbreviations: APOE, Apolipoprotein E; aMCI, amnesic mild cognitive impairment.

^aCrude.

^bAdjusted (education was not significant in either model).

Table 4

Logistic Regressions Comparing Dementia Cases to Controls and aMCI Cases to Controls for APOE-ε2, With and Without Adjustment for Educational Level

	Dementia (OR, 95% CI)		aMCI (OR, 95% CI)	
Model 1 ^a	0.11	0.01–0.94	0.40	0.09–1.71
Model 2 ^b	0.12	0.01–0.997	0.37	0.08–1.61

Abbreviations: APOE, Apolipoprotein E; aMCI, amnesic mild cognitive impairment.

^aCrude.

^bAdjusted (education was not significant in either model).